Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial

Abstract

Following MI, clinical characteristics can identify patients with increased risk of GI bleeding. The use of dual antiplatelet agents appears to be the most profound risk factor. Whether these patients would benefit from GI prophylaxis therapy remains unknown.